Caris Life Sciences (NASDAQ:CAI) Shares Gap Up on Strong Earnings

Caris Life Sciences, Inc. (NASDAQ:CAI)’s share price gapped up prior to trading on Friday following a better than expected earnings announcement. The stock had previously closed at $19.24, but opened at $21.16. Caris Life Sciences shares last traded at $21.32, with a volume of 1,119,366 shares traded.

The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.01 by $0.27. The company had revenue of $292.89 million during the quarter, compared to the consensus estimate of $281.00 million. Caris Life Sciences’s revenue for the quarter was up 125.4% on a year-over-year basis. During the same period in the previous year, the company earned ($1.73) EPS.

Caris Life Sciences News Summary

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Q4 beat and strong revenue growth — CAI reported GAAP EPS of $0.28 (well above estimates) and Q4 revenue of ~$293M, up ~125% YoY, demonstrating accelerating top‑line momentum. Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
• Positive Sentiment: Major interim Achieve 1 readout — The company announced interim data showing Caris Detect (WGS + AI) had superior sensitivity and specificity vs. methylation‑based approaches, a milestone for its MCED launch and long‑term growth potential in early cancer detection. Caris Life Sciences Completes Interim Readout of Achieve 1 Study
• Positive Sentiment: 2026 revenue guidance reaffirmed/raised — Management guided full‑year 2026 revenue to roughly $1.0B–$1.02B (above consensus), supporting sustained growth expectations as profiling services and new product launches scale. Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
• Positive Sentiment: Analyst support — Robert W. Baird initiated coverage / raised its price target (to $28 with an Outperform stance), bringing new institutional attention that can boost demand for the stock. Baird Initiates Coverage of Caris Life Sciences, Inc. (CAI) with an Outperform Rating
• Positive Sentiment: Product enhancement — Caris added an AI‑powered breast cancer signature to its Caris Molecular Tumor Board Report, expanding clinical utility and potential revenue per case in precision oncology. Caris Life Sciences (CAI) Adds New AI-powered Breast Cancer Signature to its Report
• Neutral Sentiment: Mixed analyst moves — BTIG lowered its price target from $45 to $38 but maintained a Buy rating; still bullish but the cut tempers some upside expectations. BTIG price target note
• Neutral Sentiment: Further reading / call details — The Q4 earnings call transcript and additional materials are available for investors who want management commentary on Caris Detect commercialization timing and margin cadence. Caris Life Sciences, Inc. (CAI) Q4 2025 Earnings Call Transcript

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Evercore set a $38.00 target price on Caris Life Sciences in a research report on Monday, January 5th. Wall Street Zen lowered shares of Caris Life Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Canaccord Genuity Group lifted their target price on shares of Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Monday, December 22nd. BTIG Research dropped their price objective on Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating on the stock in a report on Friday. Finally, Robert W. Baird raised their price target on shares of Caris Life Sciences from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Friday. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $33.50.

Insiders Place Their Bets

In other Caris Life Sciences news, insider Luke Thomas Power sold 62,250 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the completion of the sale, the insider directly owned 99,571 shares of the company’s stock, valued at approximately $2,646,597.18. This represents a 38.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.80% of the company’s stock.

Institutional Investors Weigh In On Caris Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CAI. Diversified Trust Co. bought a new position in Caris Life Sciences in the 4th quarter worth about $540,000. Olistico Wealth LLC purchased a new position in shares of Caris Life Sciences in the fourth quarter worth about $31,000. Zevenbergen Capital Investments LLC acquired a new position in Caris Life Sciences during the fourth quarter valued at $14,655,000. Hamilton Lane Advisors LLC purchased a new stake in Caris Life Sciences in the 4th quarter worth approximately $1,584,000. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in shares of Caris Life Sciences by 26.5% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 75,330 shares of the company’s stock valued at $2,032,000 after acquiring an additional 15,778 shares during the period.

Caris Life Sciences Trading Up 4.7%

The company has a current ratio of 9.93, a quick ratio of 9.36 and a debt-to-equity ratio of 0.79. The business has a fifty day simple moving average of $24.42. The company has a market capitalization of $5.68 billion and a P/E ratio of -43.78.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.